New oral GLP-1 agonist orforglipron cuts A1C and drives meaningful weight loss in trials, offering easier dosing than injections.
Jessica Roberts, PharmD, RPh
Advertisement
Articles by Jessica Roberts, PharmD, RPh
Advertisement
Latest Updated Articles
Beyond Injections: Orforglipron and the Future of Oral GLP-1 Receptor Agonist TherapyPublished: January 6th 2026 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5